The cell and gene therapy sectors are maturing with more and more products nearing the market, however the challenges of regulatory approval and creating a commercially viable product are far from being solved.
One of the main barriers to commercial viability is the supply chain, which contributes hugely to the overall cost of goods (COGs) and is limited by infrastructure, temperature requirements and, of course, the time frame for transportation vs. cell viability.
In this e-book we explore the impact of the supply chain on commercialisation and provide in depth insight and knowledge from the industry to prevent further failures and ensure the best levels of patient care can reach the market, including:
- Designing a robust, flexible supply chain design
- The impact of product formulation on storage needs and supply chain costs